Fig. 3. Neutralizing antibodies in mice after RBD-NP vaccines adjuvanted with TLRa-SNPs.

(A to E) Percent infectivity for all vaccine treatments at a range of week 5 serum dilutions as determined by a SARS-CoV-2 spike-pseudotyped viral neutralization assay. (F) Comparison of ID₅₀ values determined from neutralization curves. Dotted line denotes the threshold for which the FDA considers as high titer (35). (G) Relative percent infectivity of all vaccine formulations compared to convalescent human serum at 1:100 dilution. Data (n = 4 to 5) are shown as means ± SEM. P values were determined using the GLM followed by Tukey’s post hoc multiple comparisons procedure on the logged neutralization ID₅₀ values or relative infectivity comparisons. Complete P values for comparisons are shown in table S10 and S11. **P < 0.01 and ***P < 0.001.